Drug Type Bispecific antibody |
Synonyms- |
Target |
Action inhibitors, antagonists |
Mechanism αvβ1 inhibitors(Integrin alpha-V/beta-1 inhibitors), αvβ6 antagonists(Integrin alpha-V/beta-6 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Idiopathic Pulmonary Fibrosis | Preclinical | United States | 22 Jan 2021 |






